GXYLT1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A-549 human lung adenocarcinoma cell line, engineered for complete loss of GXYLT1 function. This heterogeneous population ensures robust target-gene disruption across a bulk culture, enabling reliable loss-of-function phenotypic analyses while minimizing clonal selection artifacts. The product provides an ideal model system for interrogating GXYLT1-mediated glycosylation events and their downstream consequences in a cancer-relevant cellular context.
The parental A-549 cell line is a widely characterized model of human lung adenocarcinoma, originally isolated from a 58-year-old male patient with lung carcinoma. These adherent epithelial cells exhibit morphology and molecular features consistent with alveolar type II pneumocytes and are routinely used to investigate oncogenic signaling, tumor progression, and therapeutic resistance. The knockout derivative retains the parental line??s adherent growth characteristics and is suitable for standard cell culture conditions, facilitating direct comparative studies between wildtype and GXYLT1-deficient populations.
GXYLT1 encodes a xylosyltransferase that catalyzes the addition of xylose to O-glucosylated EGF-like repeats within Notch extracellular domains. This modification, occurring in the endoplasmic reticulum, is indispensable for proper Notch folding, surface trafficking, and ligand responsiveness. GXYLT1 functionally cooperates with POGLUT1 and POFUT1, and upon ligand engagement by DLL1 or JAG1, it permits ADAM10/17 and gamma-secretase cleavage to release the Notch intracellular domain (NICD). NICD translocates to the nucleus, where it assembles a transcriptional complex with RBPJ/CSL and MAML to drive expression of HES1, HEY1, MYC, and cell cycle regulators.
In A-549 lung adenocarcinoma cells, disruption of GXYLT1 abrogates xylose addition to Notch receptors, compromising their surface presentation and ligand-induced activation. This results in decreased NICD production and attenuated expression of Notch transcriptional targets, ultimately perturbing the balance between proliferation, differentiation, and apoptosis. Given the frequent dysregulation of Notch signaling and aberrant glycosylation patterns observed in lung adenocarcinoma, this knockout model offers a physiologically relevant system for dissecting the specific contributions of GXYLT1 to oncogenic processes and for evaluating how defects in Notch glycosylation influence tumor cell behavior.
The knockout cells support a broad range of assays: western blotting and flow cytometry for total and surface Notch, luciferase reporters for Notch activity, RT-qPCR for HES1/HEY1/MYC, co-immunoprecipitation of GXYLT1 complexes, and functional readouts including proliferation, apoptosis, and spheroid formation. They are also suited for genetic rescue and high-throughput screens targeting Notch glycosylation. For further details, please contact Ascent Research.
